This year more than ever, it is critical for our community to connect and share developments and ideas, supporting precision medicine. While COVID-19 prevents us from connecting in person, we understand the importance of exchanging data and gathering virtually. QIAGEN is committed to supporting laboratories at the forefront of the fight by accelerating testing solutions in these challenging times.
Check out the full line up of workshops and the details on all the QIAGEN offerings at AMP 2020. Visit our virtual booth at AMP to talk to experts from all areas of QIAGEN’s COVID-19 solutions.
From the onset of the novel coronavirus outbreak, QIAGEN’s dedicated global teams have been working around the clock to help ensure the availability of existing testing solutions and develop new SARS-CoV-2 tests to address international testing needs.
Chat with specialists at AMP and learn more ahead of AMP on our COVID-19 resource page.
QIAGEN supports scientists seeking to better understand the SARS-CoV-2 virus with research tools, including a rapid liquid-based real-time RT-PCR approach, a full spectrum of high-performance NGS solutions and integrated bioinformatics pipelines that collectively drive a greater understanding of the multiple facets of SARS-CoV-2 biology.
Discover QIAGEN research solutions now and we look forward to connecting with you at AMP.
COVID-19 testing is impacting your lab's resources to perform complex NGS testing. The QIAseq® Multimodal NGS panels offer the only one-day single consolidated workflow for simultaneous DNA and RNA sequencing that starts with a single extraction of total nucleic acid.
Discover QIAseq Multimodal ahead of AMP, and visit us virtually to learn more.
At QIAGEN, we know kits. OEM by QIAGEN brings this expertise to you. Partner with QIAGEN to accelerate development, help ensure regulatory compliance and high quality while creating breakthrough products from Sample to Insight.
This year at AMP, OEM team members will be ready to connect and answer your questions at our virtual booth. Learn more about OEM by QIAGEN.
We have brought together a panel of experts in order to virtually bring the latest diagnostic and research solutions to you. On your own time, you can learn about the new automated and portable QIAreach system or discover the latest research advancements in NGS workflows.
This year, the QIAGEN corporate workshops will be available on-demand, starting on November 16. They are open to everyone registered to attend AMP 2020. Don’t miss out – register here.
Dr. Sonia Rao, PharmD, Senior Medical Science Liaison, QIAGEN
Dr. L. Masae Kawamura, MD, Senior Director, Medical Affairs, QIAGEN
Please join us to learn about the latest, accurate, and affordable option for COVID-19 testing and assessment. The new QIAGEN QIAreach Anti-SARS-CoV-2 Total* antibody solution offers optimal sensitivity and specificity, as well as ease of use in both installation and test performance. This solution offers qualitative results in approximately 10 minutes, and both the test, as well as the results interpretation are located at the device itself.
In this presentation, we will discuss the background of COVID-19 antibody testing and review the QIAreach Anti-SARS-CoV-2 Total Test technology and available performance/validation data.
QIAGEN will also soon launch the QIAreach SARS-CoV-2 Antigen test†, which can run simultaneously with the QIAreach Anti-SARS-CoV-2 Total test on the shared QIAreach eHub platform. QIAreach SARS-CoV-2 Antigen is currently under development and is coming later this year.
Dr. Yitzchak Goldstein, MD, Assistant Professor, Department of Pathology, Albert Einstein College of Medicine
Dr. Inessa Gendlina, MD Assistant Professor, Department of Medicine – Infectious Diseases, Albert Einstein College of Medicine
Real-Time PCR Cycle Threshold (Ct) values have become a widely debated metric in management of SARS-CoV-2 infection, however, their interpretive utility remains controversial. While Ct values can help augment the interpretation of a positive test, variability of clinical presentations and sample-related challenges necessitate that Ct values be framed within the context of the clinical presentation. Understanding additional factors such as community prevalence of disease, patient underlying immune status, and clinical stage of illness are vital to assisting clinicians in interpreting Ct values appropriately. Drs. Goldstein and Gendlina will review scenarios, opportunities and limitations in the clinical utility of Ct values.
Dr. Heba Mostafa, MD, PhD, Johns Hopkins
Jason Ong, Senior Director Marketing, NeuMoDx
Please join us to learn about NeuMoDx molecular system for high-throughput COVID-19 testing. The NeuMoDx Molecular Systems are fully automated solutions that use proprietary NeuDry technology, magnetic particle affinity capture, and real-time PCR chemistry in a multi-sample microfluidic cartridge. The systems also allow laboratories to efficiently validate their own Laboratory Developed Tests, including those provided by the WHO and CDC, to immediately improve throughput and increase the volume of testing.
In this presentation, Dr. Mostafa will discuss the COVID-19 diagnostic challenge and testing landscape. Followed by a review of the NeuMoDx molecular system and initial performance data.
Dr. Ravindra Kolhe MD, Ph.D., Vice Chair, Pathology, Medical College of Georgia at Augusta University
A better understanding of the molecular biomarkers underlying cancer development and progression is critical for improvements in patient healthcare. The profiling of actionable biomarkers has been made possible with recent advancements in NGS workflows but with the challenges of requiring parallel workflows, longer turnaround times and higher costs. In this webinar, Dr.Ravi Kolhe will discuss how his team was able to conduct comprehensive genomic profiling by using QIAseq Pan-cancer Multimodal Panel, the only single extraction NGS workflow with simultaneous library prep for both RNA and DNA.
Dr. Ravindra Kolhe will share his insights on using the QIAseq Pan-cancer Multimodal Panel for his labs comprehensive genomic profiling needs.
Dr. Özlem Karalay, Senior Scientist, Digital PCR Assay Development, QIAGEN
Digital PCR (dPCR) enables specific and sensitive detection of genetic alterations in oncogenes. It is particularly suited for the analysis of rare mutations in precious samples such as circulating cell-free DNA (ccfDNA) from blood and other body fluids. For reliable detection of single base exchanges at low frequency, both, a reproducibly working dPCR system and optimized PCR assays, are indispensable. Locked Nucleic Acid (LNA)-enhanced oligonucleotides with substantially high levels of affinity for their complementary sequences make these assays excellent tools for the detection and discrimination of highly similar DNA targets.
Here, we discuss simultaneous, high-sensitivity detection of up to three different mutations using QIAGEN’s QIAcuity dPCR system in combination with the dPCR LNA Mutation Assays.
*Product availability may vary by country specific regulatory requirements and approvals. Contact your country representative for further details.
In the United States, QIAreach Anti-SARS-CoV-2 Total testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C 263a, to perform high complexity tests.
This test has not been reviewed by the FDA.
Negative results do not rule out SARS-CoV-2 infection, particularly in those who have been in contact with the virus. Follow-up testing with a molecular diagnostic should be considered to rule out infection in these individuals.
Results from antibody testing should not be used as the sole basis to diagnose or exclude SARS-CoV-2 infection or to inform infection status.
Positive results may be due to past or present infection with non-SARS-CoV-2 coronavirus strains, such as coronavirus HKU1, NL63, OC43, or 229E.
Laboratories within the United States and its territories are required to report all positive results to the appropriate public health authorities.
†QIAreach SARS-CoV-2 Antigen Test is currently under development and coming soon.